# AbCellera Biologics Inc. Common Shares (ABCL)

> AbCellera Biologics Inc. Common Shares (ABCL) trades at $11.49 (-1.12%) as of 7:59:55 PM EST on Nov 13, 2026, -9.38% over the past month. Market cap is $3.75B, with 8.5 days to cover in short interest.

Canonical: https://massive.com/quote/abcl
Data as of: 2026-11-14T00:59:55.195Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$11.49** -0.13 (-1.12%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$11.52** +0.03 (+0.26%)
As of 7:59:55 PM EST on Nov 13, 2026 · After hours

## Stock performance

How AbCellera Biologics Inc. Common Shares (ABCL) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -1.12% |
| 1W | -3.28% |
| 1M | -9.38% |
| YTD | +235.96% |
| 1Y | +219.17% |
| 52-wk range | $2.75 – $15.02 |

From daily closes through Nov 13, 2026.

## Key statistics

Today's trading snapshot for ABCL: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $11.06 – $11.83 |
| Open | $11.75 |
| Prev close | $11.62 |
| Volume | 2.68M |
| Market cap | $3.75B |
| Shares out | 326.62M |

## Valuation and profitability ratios

Valuation and profitability ratios for AbCellera Biologics Inc. Common Shares: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 55.31 |
| P/B | 3.53 |
| P/FCF | — |
| ROE | -14.0% |
| ROA | -9.9% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 13, 2026

## Insider trading

[AbCellera Biologics Inc. Common Shares (ABCL) insider trading](https://massive.com/quote/abcl/insider-trading.md): open-market Form 4 buys and sells by AbCellera Biologics Inc. Common Shares insiders over the last 12 months.

## 8-K filings

Material corporate events AbCellera Biologics Inc. Common Shares has disclosed to the SEC on Form 8-K.

- Nov 9, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 9, 2026, AbCellera Biologics Inc. (the "Company"), issued a press release announcing its financial and operational results for the quarter ended September 30, 2026.”
- Aug 13, 2026 · Public offering
  “On August 12, 2026, AbCellera Biologics Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC and J.P. Morgan Securities LLC as the representatives of the several underwriters (the "Underwriters") relating to an underwritten public offering of (a) 17,435,897 shares (the "Shares") of the Company's common shares, no par value per share (the "Common Shares") at a price to the public of $9.75 per Share, and (b) in lieu of Shares to certain investors, pre-funded warrants to purchase up to 3,076,926 Common Shares (the "Pre-Funded Warrants", and such Common Shares issuable upon the exercise of the Pre-Funded Warrants, the "Warrant Shares") at a price to the public of $9.74999 per Pre-Funded Warrant.”
- Aug 10, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On August 10, 2026, AbCellera Biologics Inc. (the "Company") issued a press release announcing positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial evaluating ABCL635, an investigational neurokinin 3 receptor (NK3R) antagonist antibody”
- Aug 5, 2026 · Investor presentation
  “In connection with its earnings call on August 5, 2026, to discuss its results for the quarter ended June 30, 2026, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2.”
- Jul 29, 2026 · Partnership or collaboration
  “On July 29, 2026, AbCellera Biologics Inc. (the "Company") issued a press release announcing a collaboration with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. The Company will leverage its proprietary TCE platform to lead discovery and early development activities.”

## ABCL short interest

How heavily ABCL is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 8.5 |
| Short interest | 29.02M |
| Avg volume | 3.42M |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## ABCL news

The latest news and headlines about AbCellera Biologics Inc. Common Shares (ABCL).

- [AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates](https://www.zacks.com/stock/news/3026768/abcellera-biologics-inc-abcl-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3026768) · Zacks Investment Research · Nov 9, 2026 · positive sentiment
- [Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates](https://www.zacks.com/stock/news/3022350/tarsus-pharmaceuticals-inc-tars-reports-q3-loss-tops-revenue-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3022350) · Zacks Investment Research · Nov 3, 2026 · positive sentiment
- [Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates](https://www.zacks.com/stock/news/3005468/nurix-therapeutics-inc-nrix-q3-earnings-and-revenues-surpass-estimates?cid=CS-ZC-FT-fundamental_analysis|yseop_template_4-3005468) · Zacks Investment Research · Oct 12, 2026 · neutral sentiment
- [Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 \| Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera](https://www.globenewswire.com/news-release/2026/10/12/3378995/28124/en/global-synthetic-antibody-library-market-report-2026-size-and-forecast-to-2030-capitalize-on-12-cagr-and-ai-design-with-charles-river-twist-bioscience-genscript-and-abcellera.html) · GlobeNewswire Inc. · Oct 12, 2026 · positive sentiment
- [Prelude Cuts Q2 Losses and Costs 13%](https://www.fool.com/data-news/2025/08/14/prelude-cuts-q2-losses-and-costs-13/?source=iedfolrf0000001) · The Motley Fool · Aug 14, 2025 · neutral sentiment

## About AbCellera Biologics Inc. Common Shares

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 562 |
| Listed | Dec 11, 2020 |

[Company website](https://www.abcellera.com)

## FAQ

### What is the AbCellera Biologics Inc. Common Shares (ABCL) stock price today?

AbCellera Biologics Inc. Common Shares (ABCL) is trading at $11.49 (-1.12% on the day) as of 7:59:55 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is AbCellera Biologics Inc. Common Shares?

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need.

### What is the short interest in ABCL?

As of Oct 30, 2026, ABCL has 29.02M shares short and 8.5 days to cover.

### What exchange is ABCL listed on?

AbCellera Biologics Inc. Common Shares (ABCL) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ABCL quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ABCL`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [AbCellera Biologics Inc. Common Shares (ABCL) insider trading](https://massive.com/quote/abcl/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms